Clinical Trial Update: Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children [Phase 3]

View source ↗

Summary

Phase 3 trial results for Motavizumab (MEDI-524) in preventing serious RSV disease in high-risk children have been completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Motavizumab (MEDI-524) (motavizumab)

Snippet

Sponsor: MedImmune LLC | Conditions: Respiratory Syncytial Virus Infections | Phase 3 | Status: COMPLETED | Results posted: 2013-08-28